key: cord-0863269-6k4q9n61
authors: Trougakos, Ioannis P.; Terpos, Evangelos; Alexopoulos, Harry; Politou, Marianna; Paraskevis, Dimitrios; Scorilas, Andreas; Kastritis, Efstathios; Andreakos, Evangelos; Dimopoulos, Meletios A.
title: Adverse effects of COVID-19 mRNA vaccines: The Spike hypothesis
date: 2022-04-21
journal: Trends Mol Med
DOI: 10.1016/j.molmed.2022.04.007
sha: 168e5eb9f2df4e60f00dcb135616582dd69d831b
doc_id: 863269
cord_uid: 6k4q9n61

Vaccination is a major tool for mitigating the COVID-19 pandemic and mRNA vaccines are central to the ongoing vaccination campaign that is undoubtedly saving thousands of lives. However, adverse effects (AEs) following vaccination have been noted which may relate to a pro-inflammatory action of the employed lipid nanoparticles or the delivered mRNA (i.e., vaccines formulation) as well as to the herein discussed unique nature, expression pattern, binding profile and pro-inflammatory effects of the produced antigens (S protein and/or its subunits-peptide fragments) in human tissues/organs. Current knowledge on this topic mostly originates from cell-based assays or from model organisms, therefore further research on the cellular-molecular basis of the mRNA vaccines induced AEs, will guarantee safety, maintain trust, and direct health policies.

Moderna (encoded antigen: SARS-CoV-2 S protein of the Wuhan-Hu-1 strain) [18] [19] [20] were the first to receive FDA Emergency Use Authorization. In mRNA vaccines, being characterized by relatively rapid prototyping and manufacturing on a large scale, the S protein-encoding mRNA is delivered through lipid nanoparticles (LNPs) to human cells that produce the mature viral protein or related antigens (Figure 1, Key Figure) , which can exhibit a rather wide tissue/organ distribution (see below) [20] [21] [22] . In addition to the plausible pro-inflammatory role of LNPs (evidenced also from reported immediate allergic reactions) [23, 24] and of packaged mRNA, which has nonetheless been engineered via a replacement of uridine with pseudouridine [20, 25, 26] not to trigger innate immunity through pathogen-(PAMP) or damage-(DAMPS) associated molecular patterns receptors, we surmise that vaccination mediated adverse effects (AEs) can be attributed to the unique characteristics of the S protein (antigen) itself either due to molecular mimicry with human proteins or as an ACE2 ligand.

As delivered mRNAs can theoretically trigger the production of distinct antigens that can distribute systemically [20] they are radically different from conventional platforms (i.e., inactivated whole virus vaccines or even protein subunit nanoparticle vaccines -Box 2) where the produced antigen and its distribution is more predictable. As all COVID-19 vaccines rely on the S protein of the original Wuhan-Hu-1 strain [19, 20] the thus far reported differences across different vaccination platforms (see Box 2) may relate to the various vectors and formulations and/or the S protein constructs employed.

J o u r n a l P r e -p r o o f Journal Pre-proof among males after a second vaccine dose [37] ; similarly, the rate of post-vaccination cardiac AEs was higher in young boys following the second dose [38, 39] . Finally, a recent study showed an increased risk (which was however reduced versus COVID-19 patients) of neurological complications in COVID-19 vaccines recipients [34] . The molecular basis of these AEs remains largely unknown. We postulate that since most (if not all) of them are also apparent in severe COVID- 19 [31], they may be related to acute inflammation caused by both the virus and the vaccine, as well as in the common denominator between the virus and the vaccine, namely, the SARS-CoV-2 Spike (S) protein (see Box 1) . The vaccine encoded antigen (S protein) is stabilized at its pre-fusion form in the BNT162b2 and mRNA-1273 vaccines [19, 20] ; therefore, it is plausible that if entering the circulation and distributing systemically throughout the human body ( Figure 2 ) it can contribute to these AEs in susceptible individuals.

There is also evidence that ionizable lipids within LNPs can trigger pro-inflammatory responses by activating toll like receptors (TLRs) [40] . A recent report showed that LNPs used in preclinical nucleoside-modified mRNA vaccine studies are (independently of the delivery route) highly inflammatory in mice as evidenced by excessive neutrophil infiltration, activation of diverse inflammatory pathways and production of various inflammatory cytokines and chemokines [41] . This finding could explain the LNPs potent adjuvant activity supporting the induction of robust adaptive immune responses [24] . Interestingly, inflammatory responses can be exacerbated on a background of pre-existing inflammatory conditions as was recently shown in a mouse model after mRNA-LNPs administration [42] ; this effect was proven to be specific to the LNP, acting independent of mRNA cargo. J o u r n a l P r e -p r o o f Journal Pre-proof Finally, although chemical modifications in the vaccines-used RNA molecules (see above) aim to decrease TLRs sensing (and thus pro-inflammatory signals) of external single stranded RNAs, there is some evidence that modified uracils do not completely abrogate TLR detection of the mRNA; also, while efforts are made to reduce double strand (ds) RNA production, there may be low amounts of dsRNA that can occasionally get packaged within mRNA vaccines [26] .

In this context, frequent booster immunizations may increase the frequency and/or the severity of the reported AEs.

Following vaccination, a cell may present the produced S protein (or its subunits-peptide fragments) to mobilize immune responses or be abolished by the immune system (e.g., cytotoxic T cells) [25] . Consequently, the debris produced or even the direct secretion (including shedding) of the antigen by the transfected cells may release large amounts of the S protein or its subunits-peptide fragments to the circulation [19, 20] (Figure 1 ). The anti-SARS-CoV-2 vaccines mRNA-containing LNPs are injected in the deltoid muscle and exert an effect in the muscle tissue itself, the lymphatic system and the spleen, but can also localize in the liver and other tissues [21, 22, 43, 44] from where the S protein/subunits-peptide fragments may enter the circulation and distribute throughout the body. It is worth mentioning that liver localization of LNPs is not a universal property of carrier nanoparticles as specific modifications in their chemistry can retain immunogenicity with minimal liver involvement [43, 45] . In line with a J o u r n a l P r e -p r o o f Journal Pre-proof plausible systemic distribution of the antigen, it was found that the S protein circulates in the plasma of the BNT162b2 or mRNA-1273 vaccine recipients as early as day one after the first vaccine injection [46] . Reportedly, antigen clearance is correlated with the production of antigen-specific immunoglobulins or may remain in the circulation (e.g., attached in exosomes) for longer periods [47, 48] providing a reasonable (among others) explanation for the robust and durable systemic immune responses found in vaccinated recipients [49, 50] . Therefore, an extensive range of expected interactions between free-floating S protein/subunits-peptide fragments and blood (or lymph) circulating ACE2 or ACE2 expressed in cells from various tissues/organs [14] [15] [16] are likely ( Figure 2 ). This notion is further supported by the finding that in adenovirus-vectored vaccines (Box 2), the S protein produced upon vaccination has the native-like mimicry of SARS-CoV-2 S protein's receptor binding functionality and pre-fusion structure [51] .

Additional interactions with human proteins in the circulation or even the presentation to the immune system of S protein antigenic epitopes [52] mimicking human proteins (molecular mimicry) may occur [53] [54] [55] [56] . Reportedly, some of the near-germline SARS-CoV-2-NAbs against S RBD reacted with mammalian self-antigens [57] and SARS-CoV-2 S antagonizes innate antiviral immunity by targeting multiple pathways controlling interferon (IFN) production [58] . Also, a sustained elevation in T cell responses to SARS-CoV-2 mRNA vaccines was found (not yet peerreviewed data) in patients who suffer from chronic neurologic symptoms after acute SARS-CoV-2 infection as compared with healthy COVID-19 convalescents [59] . Given the reported (rare) neurological AEs following vaccination it was suggested that further studies are needed to assess whether antibodies against the vaccines-produced antigens can cross-react with regulation; anti-idiotype antibodies apart from binding to the protective neutralizing SARS-CoV-2 antibodies, can also mirror the S protein itself and bind ACE2 possibly triggering a wide array of AEs [60] . Worth mentioning is a systems vaccinology (31 individuals) approach of the BNT162b2 vaccine (two doses) effects, where anti-cytokine antibodies were largely absent or were found at low levels (contrary to findings in acute COVID-19 [61, 62] ) while two individuals had anti-IL-21 autoantibodies and two other individuals had anti-IL-1 antibodies [63] . In this context, anti-idiotypic antibodies can be particularly enhanced after frequent boosting doses that trigger very high titers of immunoglobulins [64] . Frequent boosting doses may also become a suboptimal approach as they can imprint serological responses toward the ancestral Wuhan-Hu-1 S protein, minimizing protection against novel viral S variants [65, 66] .

The potential interaction at a whole organism level of the native-like S protein and/or subunits-peptide fragments with soluble or cell membrane attached ACE2 (Figure 2 ), can promote ACE2 internalization and its degradation [67, 68] . In support, soluble ACE2 induces receptor-mediated endocytosis of SARS-CoV-2 via interaction with proteins related to RAS [69] .

Prolonged loss or reduced ACE2 activity may result in extensive destabilization of RAS which may then trigger vasoconstriction, enhanced inflammation and/or thrombosis due to unopposed ACE and angiotensin-2 (ANG II)-mediated effects [13] (Figure 2 ). Indeed, decreased ACE2 expression and/or activity contributes among others to the development of ANG IImediated hypertension in mice indicating vasculature dysfunction [67] . The baseline expression levels of ACE2 in endothelial cells or its induced expression levels upon stimulation from other J o u r n a l P r e -p r o o f Journal Pre-proof tissue-resident cells, along with the potential of endothelial cells to shed ACE2 to the circulation or their sensitivity to SARS-CoV-2 infection is debatable [70] [71] [72] [73] . Nonetheless, even relatively low (e.g., as compared to epithelial cells) ACE2 expression levels in endothelial cells [15, 16, 70, 71] along with the high expression levels of ACE2 in other cell types of the vasculature (e.g., heart fibroblasts/pericytes) [15, 74] indicates that the vasculature can be sensitive to free-floating S protein/subunits-peptide fragments ( The SARS-CoV-2 S protein induced effects in mammalian cells or model organisms Reportedly, intravenous (IV) injection of the S1 subunit in mice results in its localization in endothelia of mice brain micro-vessels showing co-localization with ACE2, caspase-3, IL-6, tumor necrosis factor alpha (TNF-α), and C5b-9; it was thus suggested that endothelial damage is a central part of SARS-CoV-2 pathology which may be induced by the S protein alone [75] .

Also, the S1 subunit (or recombinant S1 RBD) impaired endothelial function via downregulation of ACE2 [76] and induced degradation of junctional proteins that maintain endothelial barrier integrity in a mouse model of brain microvascular endothelial cells or cerebral arteries; this latter effect was more enhanced in endothelial cells from diabetic versus normal mice [77] .

Similarly, the S1 subunit decreased microvascular trans-endothelial resistance and barrier function in cultured human pulmonary cells [78] . Further, S protein disrupted human cardiac pericytes function and triggered increased pericytes production of pro-apoptotic factors causing endothelial cells death [79] . In support, administration of the S protein promoted dysfunction of human endothelial cells as evidenced by, e.g., increased expression of von Willebrand Factor [80] . Other reports indicate that S1 can directly induce coagulation by competitive binding to both soluble and cellular heparan sulphate/heparin (an anticoagulant) [81] [82] [83] [84] while cell-free hemoglobin, as a hypoxia counterbalance, cannot attenuate disruption of endothelial barrier function, oxidative stress and inflammatory responses in human pulmonary arterial endothelial cells exposed to S1 [85] . Consistently, S protein binds fibrinogen (a blood coagulation factor) and S protein virions enhanced (not yet peer-reviewed data) fibrinmediated microglia activation and induced fibrinogen-dependent lung pathology in mice [86] , while S1 binding to platelets ACE2 triggers their aggregation [84] . Interestingly, both the ChAdOx1 (AstraZeneca) and BNT162b2 vaccines can elicit anti-PF4 antibody production even in recipients without clinical manifestation of thrombosis [87] .

Intriguingly, the S protein increases human cells syncytium formation [88, 89] triggering pyroptosis of syncytia formed by fusion of S and ACE2-expressing cells [90] . Also, in cells or mouse experimental models, it was shown that S removes lipids from model membranes and interferes with the capacity of high-density lipoprotein to exchange lipids [91] , inhibits DNA damage repair processes [92] , and induces Snail-mediated epithelial-mesenchymal transition marker changes and lung metastasis in a breast cancer mouse model [93] .

In support of the possibility that there is a wide range of S protein binders, Aβ 1-42 (the 42 amino acid form of amyloid β in cerebrospinal fluid) was found to bind with high affinity the S1 subunit and ACE2 [94] . Aβ 1-42 strengthened the binding of S1 to ACE2 and increased viral entry and production of IL-6 in a SARS-CoV-2 pseudovirus infection mouse model. Data from this surrogate mouse model with IV inoculation of Aβ showed that the clearance of Aβ 1-42 in the blood was dampened in the presence of the extracellular domain of the S protein trimers [94] .

Given the wide ACE2 expression in human brain [95] , a study of particular interest showed that IV injected radio-iodinated S1 (I-S1) readily crossed by adsorptive transcytosis the blood-brain barrier in male mice, was taken up by brain regions and entered the parenchymal brain space. I-S1 was also taken up by the lung, spleen, kidney, and liver, while intranasally administered I-S1

also entered the brain, although at lower levels than after IV administration [96] . Similarly, S1 was found to disrupt the blood-brain barrier integrity at a 3D blood-brain barrier microfluidic model [97] . In support, biodistribution studies of the mRNA-LNP platform by Moderna in Sprague Dawley rats, revealed the presence of low levels of mRNA in the brain indicating that the mRNA-LNPs can cross the blood-brain barrier [22] .

Finally, it was recently reported that human T cells express ACE2 at levels sufficient to interact with the S protein [98] , while it was previously shown that SARS-CoV-2 uses CD4 to infect T helper lymphocytes and that S promotes a proinflammatory activation profile on the most potent antigen-presenting cells (APCs), i.e., human dendritic cells [99] . If these observations are confirmed, they may explain a SARS-CoV-2 vaccination-mediated AEs, namely reactivation of Varicella Zoster virus [100, 101] . [105] . Also, S promoted an inflammatory cytokine IL-6/IL-6R-induced trans signaling response and alarmin secretion in human endothelial cells, along with increased oxidative stress, induction of inflammatory paracrine senescence and higher levels of leukocyte adhesion [106] . Other reports indicate that S triggers an inflammatory response signature in human corneal epithelial cells [107] , increases oxidative stress and DNA double strand breaks in human PBMCs post-vaccination [108] and binds to lipopolysaccharide boosting its proinflammatory activity [109, 110] . Further, S protein induced neuroinflammation and caspase-1 activation in BV-2 microglia cells [111] and blocked neuronal firing in sensory neurons [112] . The S protein-induced systemic inflammation may proceed via TLR2-dependent activation of the NF-kB pathway [113] , while structure-based computational models showed that S exhibits a high-affinity motif for binding T cell receptors (TCRs) and may form a ternary complex with histocompatibility complex class II molecules; indeed, analysis of the TCR repertoire in COVID-19 patients showed that those with severe hyperinflammatory disease exhibit TCR skewing consistent with superantigen (S protein) activation [114] . At in vivo models, S protein activated macrophages and contributed to induction of acute lung inflammation in mice [115] , while intratracheal instillation of the S1 subunit in transgenic mice overexpressing human ACE2 induced severe COVID-19-like acute lung injury and inflammation.

These effects were milder in wild type mice indicating the phenotype dependence on human ACE2 expression [78] . Consistently, S1 has been found to act as a PAMP that, via pattern recognition receptor engagement, induces viral infection-independent neuroinflammation in adult rats [116] .

These observations correlate with the finding of a systemic inflammatory signature after the first BNT162b2 vaccination which was accompanied by TNF-α and IL-6 upregulation after the second dose [117] ; these effects may also relate (see above) to a pro-inflammatory action of the mRNA-LNP platform. Supportively, in a thorough systems vaccinology study of the and -boost (d7PB) doses and other vaccine types (e.g., inactivated, or live-attenuated vaccines) exhibited weak correlation both between d7PP and d7PB as well as with other vaccines [63] .

These findings suggest the evolvement of novel genomic responses after the second dose and, J o u r n a l P r e -p r o o f more importantly, the unique biology of mRNA vaccines versus other more conventional platforms. Of particular interest is also the report of a cytokine release syndrome (CRS; an extremely rare immune-related AE of immune checkpoint inhibitors) post-BTN162b2 vaccination in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy; the anti-PD1 blockade-mediated CRS was evidenced by increased inflammatory markers, thrombocytopenia, elevated cytokine levels and steroid responsiveness [118] . These proinflammatory effects could be particularly pronounced in the elderly since recent data revealed that senescent cells become hyper-inflammatory in response to S1 subunit, followed by increased expression of viral entry proteins and reduced antiviral gene expression in nonsenescent cells through a paracrine mechanism [119] .

Anti-SARS-CoV-2 mRNA vaccines induce durable and robust systemic immunity and thus their contribution in mitigating COVID-19 pandemic and saving thousands of lives is beyond doubt.

This technology has several advantages over conventional vaccines [120] and opens a whole new era of novel vaccines development against various infectious diseases and beyond, including cancer. Based on currently available molecular insights (mostly in cell-based assays and model organisms), we hypothesize that the rare AEs reported following vaccination with S protein encoding mRNA vaccines may relate to the nature and binding profile of the systemically circulating antigen(s) (Figures 1, 2) , although the contribution of the LNPs and/or the delivered mRNA is likely also significant [24, 26, 41] . Therefore, the possibility of subclinical J o u r n a l P r e -p r o o f organ dysfunction in vaccinated recipients which could nonetheless increase the risk for future e.g., (cardio-) vascular or inflammatory diseases should be thoroughly investigated. For example, given that severe COVID-19 correlates with older age, hypertension, diabetes and/or cardiovascular disease, which all share a variable degree of ACE2 signaling deregulation, additional ACE2 down-regulation induced by vaccination may further amplify unbalanced RAS.

Regarding localization of LNPs in the liver and consequent antigen expression, it is worth mentioning that liver is continuously exposed to a multitude of self and foreign antigens and can mount efficient immune responses against pathogens as it hosts convectional APCs (e.g., dendritic cells, B cells and Kupfer cells). Additional liver cell types, such as liver sinusoidal endothelial cells, hepatic stellate cells and hepatocytes have also the capacity to act as APCs [121] . It is plausible, though yet unproven, that as the S protein is produced in liver cells, both conventional and unconventional APCs may prime adaptive but also innate immune responses in the liver's immunological niche. Despite the liver's major tolerogenic role [122] the sustained expression of S-related antigens (Figure 1) can potentially skew the immune response towards autoimmune-like tissue damage, like in the observed cases of autoimmune hepatitis following vaccination [123, 124] . It therefore merits further investigation whether LNPs can transfect any other non-immunological body tissues bearing cells that can act as unconventional APCs, thus inducing a sustained immune response but also a self-response, as in cases of chronic viral infections [125] . Clinician's Corner  Given the plethora of existing data on the available mRNA vaccines, a major "known" is that in the short-term, mRNA vaccines are well tolerated by the recipient, as well as that they can induce a robust immune response and therefore provide a prolonged protection against severe COVID-19 (including emerging Variants of Concern); thus, vaccination remains a major tool for mitigating the COVID-19 pandemic and saving thousands of lives.

 It is well established that the risk for severe COVID-19 increases with age or preexisting comorbidities. Given the "unknowns" discussed herein, boosting doses in healthy children and even adolescents should be delivered only if the benefit-risk profile is clearly established. 

through the receptor binding domain (RBD) of its protruding S glycoprotein [127] , which remains in a metastable pre-fusion state, through the association of subunits 1 (S1) and 2 (S2) via non-covalent interactions [18, 19] ; the infection process is also facilitated by host proteases [127, 128] . Whereas in most of SARS-CoV-2 infected carriers the virus is contained in the upper RS resulting in either no (asymptomatic) or mild symptoms [1, 2] , a minority will require hospitalization. This is due to severe symptoms developed due to extensive inflammation, a process often referred to as a "cytokine storm", causing ARDS which may be accompanied by viremia and can lead to systemic multi-organ collapse [7] [8] [9] [10] . The risk for severe COVID-19 increases significantly with age or preexisting comorbidities [1, 2, 129] and younger individuals have a substantially lower risk, even as compared to influenza infection [129] , for developing severe COVID-19 [130, 131] . It has been postulated that higher paediatric innate interferon responses restrict viral replication and disease progression [132] . Supportively, in a recent trial where young people were intentionally exposed to a low dose of SARS-CoV-2, nearly half of the participants did not become infected, some were asymptomatic and those who developed COVID-19 reported mild-to-moderate symptoms, including sore throats, runny noses, sneezing and loss of smell and taste; fever was less common, and no one developed persistent cough [133] .

SARS-CoV-2-infection in healthy individuals triggers innate as well as adaptive immune system responses, i.e., CD4 + and CD8 + T cells and antibodies [including neutralizing antibodies (NAbs)] produced by terminally differentiated B cells, which altogether suppress the extent of infection J o u r n a l P r e -p r o o f [132, 134, 135] . As SARS-CoV-2 initially infects the upper RS, defensive immune responses start to develop at respiratory mucosal surfaces followed by systemic immunity [136, 137] . These immune responses are age-and gender-dependent and may either poorly mount in a background of genetic causes and preexisting morbidities or become very intense and essentially uncontrolled in severe disease leading to ARDS and systemic failure [11] [12] [13] .

In viral vector vaccines, the S protein coding information is delivered via a replication-deficient adenoviral vector system that contains an encoding dsDNA. In this case, transcripts from adenoviral vectors are generated in the cell nucleus. Here, a major reported AE is immune thromboembolism (including cerebral venous sinus thrombosis) in various organs probably through excessive innate immune system and endothelial activation [138] . Apart from the S protein itself, AEs can be also attributed to background expression of remaining adenoviral genes or to persisting adenovirus-vector DNA in a transcriptionally active form. Further concerns refer to the presence of other contaminant proteins, remnants of the vaccine production line and to pre-existing anti-vector immunity [20] ; this last issue does not apply to the recombinant ChAdOx1-S (Oxford-AstraZeneca) vaccine which employs a non-human adenovirus vector. More importantly, the infectious cycle of SARS-CoV-2 takes place exclusively in the cytoplasm and thus there has been no evolutionary pressure against the presence of splice donor and acceptor sites in its genes. This is a major difference with mRNA vaccines that J o u r n a l P r e -p r o o f function in the cytoplasm, since various spliced transcripts from adenoviral vectors can be generated in the cell nucleus [56] .

In protein subunit nanoparticle vaccines (e.g., NVX-CoV2373), the S protein is harvested in a cell culture system, purified, and delivered as a trimer via a nanoparticle assembly in an adjuvant. Although preliminary trials indicate that these vaccines can trigger robust immunity

[139] reports on AEs are still scarce due to the limited number of vaccinations data.

Finally, in the conventional vaccines, the whole virus is inactivated and inoculated using an appropriate adjuvant [26] . A significant benefit is that whereas in the previously discussed technologies the S protein is the sole source of immunogenic epitopes here a wide repertoire of epitopes in other viral proteins is presented. Possible disadvantages include lower immunogenicity, production issues, AEs due to used adjuvant(s) (e.g., aluminum hydroxide) as well as issues that relate to incomplete inactivation of the virus. Given that these vaccines have not reached mass production, reports on possible AEs do not exist. where S1 is exposed to the extracellular space (e.g., may face circulation). Although the extend of antigen expression per cell remains unknown it is reasonable to assume that this process results in rather extended decoration of transfected cells with S. Furin-mediated proteolytic cleavage (as in SARS-CoV-2 infected cells) in the absence of a mutated S1/S2 furin cleavage site at the Trans Golgi network may result in shedding of cleaved S1 and conversion of S2 into its J o u r n a l P r e -p r o o f post-fusion structure (S2*). Antigen sorting and trafficking may also induce the release of S containing exosomes. Shown events will occur in the apical and/or basolateral surfaces of polarized (e.g., epithelial) cells. The Pfizer-BioNTech, Moderna used constructs do not contain a mutated S1/S2 furin cleavage site. Further research will clarify the impact of the S1/S2 subunits stabilizing D614G (or other) mutation or of a mutated furin cleavage site in antigen distribution,  What would the impact be of excessive "decoration" of non-professional antigen presenting transfected human (e.g., liver) cells with transmembrane S protein?  Does the antigen or related subunits/peptides fragments leak in the circulation, and if yes, in which form, at which concentration and for how long -is there any association with the vaccines-mediated immune responses?

 Is the probable binding of the antigen to ACE2 in the vasculature accountable for the cardiovascular, metabolic, or other (e.g., inflammation-related) reported AEs?

 Does the antigen cross the blood-brain barrier or expressed in the brain?

 Is there any noteworthy molecular mimicry (especially of the major antigenic sites) between the S protein and the human proteome?

 What is the profile of mucosal immunity induced by the mRNA COVID-19 vaccines? J o u r n a l P r e -p r o o f  It is that vaccination (two doses)-mediated immunity against the used ancestral antigen (Wuhan-Hu-1 S protein) wanes over time or we simply partially lose protection due to evolutionary leaps (e.g., Omicron) of the S protein -in that sense do we really need boosting doses with the same antigen?

 Does boosting, apart from raising titers also promotes antibody diversification?

 What would the profile of immune responses and AEs be following mRNA-guided expression of the S protein in its closed (not prone to ACE2 binding) form?

J o u r n a l P r e -p r o o f

Individual and community-level risk for COVID-19 mortality in the United States

Age-specific mortality and immunity patterns of SARS-CoV-2

Evolution of antibody immunity to SARS-CoV-2

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Virological assessment of hospitalized patients with COVID-2019

Clinical and immunological features of severe and moderate coronavirus disease 2019

Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Extrapulmonary manifestations of COVID-19

A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators

Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Long COVID in a prospective cohort of home-isolated patients

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

Mechanisms of SARS-CoV-2 entry into cells

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines

Future considerations for the mRNA-lipid nanoparticle vaccine platform

Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines

Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination

2021) mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine

Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients

Peptide mimicrying between SARS coronavirus spike protein and human proteins reacts with SARS patient serum

Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine

SARS-CoV-2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms

Vaccine-induced COVID-19 mimicry syndrome

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

SARS-CoV-2 Spike Antagonizes Innate Antiviral Immunity by Targeting Interferon Regulatory Factor 3

Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination

A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Diverse functional autoantibodies in patients with COVID-19

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece

Immune imprinting and SARS-CoV-2 vaccine design

Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination

Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism

ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Pathological Ace2-to-Ace enzyme switch in the stressed heart is transcriptionally controlled by the endothelial Brg1-FoxM1 complex

Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells

COVID-19 Vasculopathy: Mounting Evidence for an Indirect Mechanism of Endothelial Injury

SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in β Cells

Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein

SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2

SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity

The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Κ18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells

The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease

SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin

SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

Cell-Free Hemoglobin Does Not Attenuate the Effects of SARS-CoV-2 Spike Protein S1 Subunit in Pulmonary Endothelial Cells

SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation

SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spikemediated syncytia formation

D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage

SARS-CoV-2 spike protein removes lipids from model membranes and interferes with the capacity of high-density lipoprotein to exchange lipids

SARS-CoV-2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro

Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail

The Effects of Aβ(1-42) Binding to the SARS-CoV-2 Spike Protein S1 Subunit and Angiotensin-Converting Enzyme 2

The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains

The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice

SARS-CoV-2 Spike Protein Disrupts Blood-Brain Barrier Integrity via RhoA Activation

T-Cell Expression of Angiotensin-Converting Enzyme 2 and Binding of Severe Acute Respiratory Coronavirus 2

SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2. Vaccines (Basel)

Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells

SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism

Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity

SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling

SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells

SARS-CoV-2 spike protein-induced host inflammatory response signature in human corneal epithelial cells

Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus

SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity

Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by α-1 Antitrypsin

SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia

SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia

SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway

Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation

Spike protein of SARS-CoV-2 activates macrophages and contributes to induction of acute lung inflammation in male mice

SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients

Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2

Senolytics reduce coronavirus-related mortality in old mice

2021) mRNA-Based Vaccines. Vaccines (Basel)

The liver as an immunological organ

Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells

Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up?

Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed

The ABCs of Antigen Presentation by Stromal Non-Professional Antigen-Presenting Cells

SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review

On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community

Local and systemic responses to SARS-CoV-2 infection in children and adults

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

Single-cell landscape of immunological responses in patients with COVID-19

are depicted. ANG II binding and activation of the type 1 receptor (AT1R) promotes inflammation, fibrotic remodeling, and vasoconstriction, whereas the ANG

ANG (1-9) peptides binding to MAS receptor (MASR) activate anti-fibrotic, anti-inflammatory pathways and vasodilation. Additional modules of RAS

Acknowledgments Not applicable -authors received no funding for the preparation of this